The Association of the British Pharmaceutical Industry (ABPI) welcomes its newest member Santen UK.Read more
Commenting on the NHS Clinical Commissioners’ call for the ‘removal of barriers preventing CCGs from prescribing Avastin to treat wet AMD’, Paul Catchpole, ABPI’s Director of Value and Access, says “seeking to bypass the regulatory system potentially threatens patient safety”.Read more
Responding to today’s publication of Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold by the Centre for Health Economics Paul Catchpole, ABPI’s Director of Value and Access, says the research “is likely to be of some academic interest but should not be used as a basis for policy or decision making.”Read more
David Taylor, Emeritus Professor of Pharmaceutical and Public Health Policy at University College London (UCL), on why recent decisions regarding the Cancer Drugs Fund are blind to our national interests and are insensitive to vulnerable patients.Read more
Our website is not compatible with Internet Explorer 8. If you are experiencing problems with scrolling please upgrade to a later version or use another browser.